Vietnam) were obtained. Associations were assessed using logistic regression and multinomial logistic regression with polymyositis (PM) as the reference group. Results: Data regarding 3,196 patients were analysed. The UK was the largest contributor (n=1,307). The most common diagnoses were dermatomyositis (34%), PM (32%) and connective tissue disease (CTD)-overlap myositis (15%). In those with anti-synthetase syndrome (7%), 85% had muscle weakness, 86% ILD and 58% arthritis. Overall, 43% had a myositis specific antibody, most commonly anti-Jo1 autoantibodies (20%). Glucocorticoid usage was noted in 98%. Most commonly used disease modifying agents were methotrexate (71%) and azathioprine (50%). Malignancy occurred in 9% and was associated with a diagnosis of dermatomyositis (Relative Risk Ratio [RRR] 1.68, 95% CI 1.09-2.56, p=0.018). Cardiac involvement occurred in 9%, most commonly in those with CTD-overlap myositis (13%), and was associated with a higher Health Assessment Questionnaire disability index (1 versus 0.75, OR 1.40, 95% CI 1.03-1.91, p=0.031). Dysphagia occurred in 39% and was associated with a diagnosis of CTD-overlap myositis (RRR 2.25, 95% CI 1.61-3.15, p<0.001). Background: There is an unmet need for biomarkers in Systemic Sclerosis (SSc). Despite its shortcomings, the modified Rodnan skin score (mRSS) has remained the standard disease assessment tool for SSc. Expression of certain genes, cartilage oligomeric matrix protein (COMP), thrombospondin-1 (THS1), interferon-induced 44 (IFI44) and sialoadhesin (SIG1), and, more recently, Tenascin-C (TNSC), have been shown to correlate with skin fibrosis. However, assessment of the expression of these genes requires a skin biopsy. Hence, we used an open-ended approach to identify a serum-based biomarker of SSc. Objectives: To identify small molecules in serum that correlate with mRSS and profibrotic genes that are upregulated in skin of SSc patients Methods: We obtained serum and skin biopsies from 25 consenting adult patients with SSc and serum from 25 age-and sex-similar controls. mRNA levels of five genes: COMP, THS1, IFI44, SIG1, and TNSC were estimated as fold-change relative to Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a housekeeping gene. H 1 NMR (Nuclear Magnetic Resonance) based metabolomics studies were performed on the sera using standard protocols. Principal component analysis (PCoA) and Partial Least Squares Discriminant Analysis (PLSDA) were used to delineate metabolites that were different between patients and healthy controls. Then spearman correlations (ρ) of these metabolites with mRSS and the fold-expression of the five pro-fibrotic genes were estimated. Results: H 1 NMR based metabolomics identified 126 peaks that were different between patients and controls. Out of these, the levels of glycine had the best correlation with pro-fibrotic gene expression (ρ=0.5, p<0.05 for IFI44; ρ=0.44,
SAT0375 METABOLOMICS OF SERA REVEALS POTENTIAL BIOMARKERS OF SKIN FIBROSIS IN SYSTEMIC SCLEROSIS THAT CORRELATE WITH PRO-FIBROTIC GENE EXPRESSION IN SKIN BIOPSIES
Background: There is an unmet need for biomarkers in Systemic Sclerosis (SSc). Despite its shortcomings, the modified Rodnan skin score (mRSS) has remained the standard disease assessment tool for SSc. Expression of certain genes, cartilage oligomeric matrix protein (COMP), thrombospondin-1 (THS1), interferon-induced 44 (IFI44) and sialoadhesin (SIG1), and, more recently, Tenascin-C (TNSC), have been shown to correlate with skin fibrosis. However, assessment of the expression of these genes requires a skin biopsy. Hence, we used an open-ended approach to identify a serum-based biomarker of SSc. Objectives: To identify small molecules in serum that correlate with mRSS and profibrotic genes that are upregulated in skin of SSc patients Methods: We obtained serum and skin biopsies from 25 consenting adult patients with SSc and serum from 25 age-and sex-similar controls. mRNA levels of five genes: COMP, THS1, IFI44, SIG1, and TNSC were estimated as fold-change relative to Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a housekeeping gene. H 1 NMR (Nuclear Magnetic Resonance) based metabolomics studies were performed on the sera using standard protocols. Principal component analysis (PCoA) and Partial Least Squares Discriminant Analysis (PLSDA) were used to delineate metabolites that were different between patients and healthy controls. Then spearman correlations (ρ) of these metabolites with mRSS and the fold-expression of the five pro-fibrotic genes were estimated. Results: H 1 NMR based metabolomics identified 126 peaks that were different between patients and controls. Out of these, the levels of glycine had the best correlation with pro-fibrotic gene expression (ρ=0. Background: Autoantibodies (Abs) against 5'-Nucleotidase, Cytosolic 1A (NT5C1A) have been portrayed as a potential diagnostic aide in distinguishing inclusion body myositis (IBM) and polymyositis (PM) in adults. However, 4-21% of dermatomyositis (DM) patients also have Abs to NT5C1A. Objectives: The prevalence and clinical features of anti-NT5C1A Abs in juvenileonset myositis (IIM) patients is unknown, so we sought to examine this in a large cohort. Methods: We screened 384 juvenile IIM patients meeting probable or definite Bohan and Peter criteria for anti-NT5C1A Abs by immunoblotting for the full length NT5C1A protein in transfected and non-transfected lysates. Clinical characteristics and HLA typing were compared between juvenile IIM patients who were anti-NT5C1A positive (Ab+) and those who were anti-NT5C1A negative (Ab-). Results: In this cohort, 29% (103) of juvenile DM, 15% (3) of juvenile PM, and 37% (15) of juvenile overlap myositis patients tested positive for anti-NT5C1A Abs. Compared with anti-NT5C1A Ab-patients, anti-NT5C1A Ab+ juvenile IIM patients showed a similar distribution of race, gender, and association with myositis-specific Abs. However, NT5C1A Ab was associated with anti-p155/140 Abs (p=0.05). The only observed clinical difference was an increased frequency of V-or shawl-sign rashes ever present (44% vs. 26%, p=0.002). Disease severity was increased in anti-NT5C1A Ab+ patients, based on more frequent hospitalizations (p=0.02), more medications used (p<0.001), and more treatment trials per year (p<0.001). Additionally, pulse steroids (p<0.001) and intravenous immunoglobulin therapy (p=0.008) were prescribed more frequently in anti-NT5C1A Ab+ than Ab-patients. The HLA alleles DRB1*07 (20% vs. 9%, p<0.05) and DQA1*0201 (21% vs. 7%, p<0.01) were present more frequently in anti-NT5C1A Ab-compared to Ab+ patients. Conclusions: Anti-NT5C1A Abs are commonly present in juvenile DM and juvenile overlap myositis patients, and are present more frequently in patients with anti-p155/140 Abs, but are also seen in association with other myositis specific Abs. Consistent with data in adult IIM patients, anti-NT5C1A Abs have few distinguishing clinical features in juvenile myositis, but are associated with increased illness severity marked by increased hospitalizations and receipt of additional therapy. Disclosure of Interest: R. Yeker: None declared, I. Pinal-Fernandez Grant/ research support from: The Myositis Association, T. Kishi Grant/research support
